Papilledema in a Nine-Month-Old: Why Convenience Isn't the First Question in Severe CAPS
Both anakinra and canakinumab work in this disease family. Today's active eye finding is what actually decides which one has to come first.
Leo P. is nine months old and has had a fine, migratory urticarial-appearing rash since his second week of life, present essentially every day of his short life without ever fully clearing. Over the past two months his parents noticed he seemed to startle less at loud sounds than he used to, prompting an audiology referral that found early sensorineural hearing loss, and a pediatric ophthalmology exam obtained as part of the same diagnostic workup found bilateral papilledema — swelling of the optic disc from raised intracranial pressure, a finding serious enough on its own to represent a potential threat to his vision if the underlying process driving it isn't controlled promptly. Genetic testing confirmed a pathogenic NLRP3 variant, and the combination of neonatal-onset rash, sensorineural hearing loss, and active CNS involvement places him at the most severe end of the CAPS spectrum — the phenotype historically called NOMID or CINCA, rather than the milder, episodic presentations seen in familial cold autoinflammatory syndrome or Muckle-Wells syndrome.
A lumbar puncture performed as part of today's workup showed an elevated opening pressure and a mildly elevated white cell count, consistent with the chronic aseptic meningitis that defines the CNS component of this phenotype — an active, ongoing process rather than a resolved prior insult, and the specific finding that makes today's treatment decision urgent rather than routine. His parents, both first-time parents managing a diagnosis they had never heard of three weeks ago, have said plainly that the idea of a daily injection in their infant is frightening to them, though they have not yet said it is something they cannot do.
Two IL-1-targeted drugs have trial evidence in this disease family, but not the same amount and not in the same patients — Goldbach-Mansky and colleagues studied anakinra in NOMID specifically, Lachmann and colleagues studied canakinumab in the milder CAPS phenotypes. Which of them actually matches what is happening in his eyes and his spinal fluid right now is what the team is working through.
What today’s eye finding actually requires
Active papilledema and an elevated CSF opening pressure today mean his CNS disease is genuinely active, not a historical finding we're just documenting. Goldbach-Mansky's pivotal trial in this exact severe phenotype enrolled patients with active CNS disease like his and showed rapid, individually titratable control with anakinra. I'd start there — the ability to adjust dose week to week matters when we're actively trying to bring intracranial pressure down.
I don't dispute the trial-population match, but I want to name a real risk on the other side: anakinra's short half-life means a single missed dose in a nine-month-old — and his parents have told us directly they're frightened by the idea of a daily injection — creates an actual gap in coverage during an active CNS crisis, not a theoretical one.
I want to be careful not to overstate my own alternative, though. Canakinumab's pivotal randomized CAPS trial — Lachmann and colleagues, 2009 — enrolled patients four years and older with the FCAS and Muckle-Wells phenotypes; the NOMID experience is a separate, small open-label study, Sibley and colleagues in 2015, where response was less complete than in milder CAPS even at double the usual dose. Its labeled CAPS indication covers FCAS and Muckle-Wells in patients four and older, which he is not. So my point is narrower than “use the other drug”: consistent exposure is a real clinical variable and I don't want it treated as mere convenience — but the drug that would deliver it is off-label here on both phenotype and age.
I think you're both right about different timeframes. Today's crisis — active papilledema, elevated opening pressure — calls for the drug with the closest trial match to exactly this presentation, and that is anakinra, which is also the agent actually approved for NOMID with no lower age limit. What I'd resist is treating the adherence problem as though it has a ready pharmacologic answer waiting a year out. It may not: he will still be well under four, still outside the labeled phenotype, and the NOMID-specific data on the alternative are thinner, not merely less studied.
I don't think we have to pick one drug for his whole childhood tonight. I'd start anakinra now, and treat the injection burden as something to solve first with support — nursing teaching, a home-health visit, whatever makes the daily dose survivable for these two parents — rather than as an argument for a drug he isn't eligible for. If it genuinely can't be sustained, an off-label switch becomes a real conversation, but as a documented decision with its own consent discussion, not as the default next chapter.
Anakinra was started that day — the agent actually approved for this phenotype, and without a lower age limit — with ophthalmology and repeat lumbar puncture follow-up scheduled to track papilledema and CSF findings specifically. The Clinical Pharmacologist's adherence concern was addressed with home-nursing support and injection teaching rather than with a scheduled drug switch, since the lower-frequency alternative would be off-label on both phenotype and age for years yet.
Not agreed, and named directly: how quickly “demonstrably resolved” should be interpreted once treatment begins. The Pediatric Rheumatologist would not consider an off-label switch at all until CSF findings have fully normalized, and is not persuaded it should happen even then given the weaker NOMID data; the Clinical Pharmacologist holds that if the family cannot reliably deliver a daily injection, an inconsistently given labeled drug is not obviously safer than a consistently given off-label one, and wants that trade named rather than settled by regulatory status alone. The Pediatrician did not resolve this between them, only confirmed that the question turns on how the family actually copes over the next several months, and that both would reassess together rather than let it default to whichever specialist happens to see him next.